Eniax Signs Cerba, Analiza, and Oftalvist as Clients and Aims for 1M in Sales in 2023

Eniax continues to grow in Spain. The company of Latin American origin, which uses artificial intelligence (AI) to reduce patient absenteeism in medical and hospital environments, has signed three new clients in national territory, according to Aline Gómez-Acebo, CEO of Eniax.

The company already offers its services to Cerba, Analiza, which is a provider of diagnostic tests such as clinical analysis, diagnostic imaging or pathology, and Oftalvist, which is a national ophthalmology group dedicated to the prevention, diagnosis, and treatment of eye diseases, as well as comprehensive vision care in more than 40 centers spread over thirteen provinces of Spain. Its medical staff is articulated of more than seventy specialists.

Likewise,  the Spanish subsidiary of Eniax, which completed one year of activity in March 2022, has closed its first year with a turnover of half a million euros and the forecast for next year is to double the figure, up to €1 million.  On a global scale, the operator registers revenues of €3 million.

Read more about Eniax and find the most important financial news of the day with our companion app Born2Invest.

Eniax expects to bill one million euros in Spain next year

The company works from a natural language processing engine called Patricia, an assistant that has been trained on more than eighty million cases. Eniax also has operators who manage any administrative process that involves prior planning. The company’s business model is that of a  Business-to-Business  (B2B) company and charges for the use of its technology.

Globally, 20% of patients do not attend their doctor’s appointments. A problem that causes delays in health care. When the schedules of a medical center (especially those with high latency) are managed with maximum efficiency, up to 50% of the slots are freed up, allowing more patients to be attended, and optimizing time.

The digital health company works using technology to manage more than five million appointments a month in more than 200 clinics in  Chile, Argentina, Peru, Portugal, and Spain.

The company is also carrying out projects for insurance companies such as follow-up of prospects and appointment assistance to policyholders, while helping “in the management of public health waiting lists, facilitating communication,” said Gómez-Acebo. The CEO of Eniax acknowledges that the company’s next step is to strengthen southern Europe and open up the market in Brazil.

“We have also incorporated the voice service in Spanish that is working with several clients and we are going to start with this service in Portugal in April,” he added.

Eniax’s origins date back six years in Santiago de Chile. Among its owners is Pablo Izquierdo, who for fourteen years was manager of the technical services company for the health sector Imed and director and president of AFP Modelo, a pension fund insurer. It is also owned by Milan Djidara, co-founder of the Eniax group and a  software engineer.

Eniax also works with some medical centers in Spain, such as the HLA Moncloa University Hospital in Madrid, from Grupo Asisa. Another example of Eniax integration is the case of Cedisa in Granada. This diagnostic center collaborates with the Andalusian health service in screening programs for the early detection of breast cancer.

__

(Featured image by tungnguyen0905 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.